Public Comment from Doctors for America to the Centers for Medicare and Medicaid Services on “Proposed National Coverage Determination for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease” (CAG-00460N)
Written Testimony of Reshma Ramachandran, M.D., M.P.P. at Hearing on “FDA User Fee Reauthorization: Ensuring Safe and Effective Drugs and Biologics” Subcommittee on Health
Press Release: Doctors for America’s FDA Task Force Physician Lead Dr. Reshma Ramachandran Serves as Expert Witness, Offers Congressional Testimony on FDA Reform
President Biden Announces New Actions to Protect Americans Against the Delta and Omicron Variants as We Battle COVID-19 this Winter
